(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 October 2012 (04.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/131555 A3

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 16/46* (2006.01)

(21) International Application Number:
PCT/IB2012/051410

(22) International Filing Date:
23 March 2012 (23.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/467,727 25 March 2011 (25.03.2011) US

(71) Applicant *(for all designated States except US)*: **GLENMARK PHARMACEUTICALS S.A.** [CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BLEIN, Stanislas** [FR/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **SKEGRO, Darko** [HR/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **WASSMANN, Paul** [DE/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
27 December 2012

(54) Title: HETERO-DIMERIC IMMUNOGLOBULINS

FIG. 1

```
                                340       350       360       370       380
                                .    ....|....|....|....|....|....|....|....|...
Human IgG1 CH3 domain           ~~GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
CH3-BT alpha domain             ~~.......................K.V...T..................
CH3-BT beta domain              ~~......E.A.F............T.V...T..................

                                390       400       410       420       430
                                .|....|....|....|....|....|....|....|....|...
Human IgG1 CH3 domain           NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
CH3-BT alpha domain             ...Y............S.V.W.N.........................
CH3-BT beta domain              .....D..L.E.....C.S.R.R.........................

                                440
                                .|....|..
Human IgG1 CH3 domain           KSLSLSPGK
CH3-BT alpha domain             .........
CH3-BT beta domain              .........
```

(57) Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.

WO 2012/131555 A3